[Scleroderma--systemic sclerosis. Serology, lung function and survival].
Patients with systemic sclerosis (SSc) were studied with regard to the presence of antinuclear antibodies (ANA) and their clinical correlates (n = 230), pulmonary function (n = 176), and mortality and causes of death (n = 344). ANA were found in 85%. Anti-centromere antibodies were found in 34%, anti-Scl-70 antibodies in 13% and anti-U1-RNP antibodies in 6.5%. These serological groups were associated with limited SSc, diffuse SSc, and myositis/arthritis, respectively. The most prevalent finding at first lung function test was isolated reduction of diffusion capacity (47%). Further deterioration of diffusion capacity was related to the presence of anti-centromere antibodies and increased sedimentation rate. The standardized mortality rate (SMR) was 2.9, higher in young patients (SMR = 13) and patients with diffuse SSc (SMR = 4.5).
Ullman
S
S
Dermatologisk afdeling, H:S Bispebjerg Hospital.
Halberg
P
P
Wiik
A
A
Jacobsen
S
S
D000293:Adolescent; D000328:Adult; D000368:Aged; D000974:Antibodies, Antinuclear / Q000032:analysis; D001799:Blood Sedimentation; D002423:Cause of Death; D002503:Centromere / Q000276:immunology; D005260:Female; D006801:Humans; D008176:Lung Volume Measurements; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012595:Scleroderma, Systemic / Q000276:immunology / Q000401:mortality / Q000503:physiopathology; D015996:Survival Rate
D000974:Antibodies, Antinuclear
Sklerodermi--systemisk sklerose. Serologi, lungefunktion og overlevelse.